StocksFin Logo
ACADIA Pharmaceuticals Inc. country of incorporation
|
|
Mr. Stephen Davis
|
510 employees
NASDAQ | Healthcare | Biotechnology
Roivant Sciences Ltd. country of incorporation
|
|
863 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Nov 3, 2022 Reporting Period
$130.71M -0.7% vs. Q321 Revenues Q322
98.37% 3.6% vs. Q321 Gross Profit Margin
-20.8% ! -89.3% vs. Q321 Net Profit Margin
-727k ! 95.7% vs. Q321 Free Cash Flow Q322
$-0.17 ! -88.9% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Q223 reported Nov 14, 2022 Reporting Period
$12.53M -10.4% vs. Q222 Revenues Q223
70.95% 30.5% vs. Q222 Gross Profit Margin
-1000% ! 0% vs. Q222 Net Profit Margin
-452.27M ! -275% vs. Q222 Free Cash Flow Q223
$-0.42 ! -38% vs. Q222 EPS Q223
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Dec 31, 2022
Quick Ratio
4.23
6.25
Current Ratio
4.47
6.74
Cash Ratio
1.33
6.25
Price to Book
6.22
5.96
Price to Sales
20.26
100
Price to Earnings
-24.35
-4.05